Since initiating our first milestone-based therapeutic antibody partnership in October 2012, IONTAS have successfully completed 34 antibody discovery projects with 23 European and USA-based partners. We have also granted licenses to our antibody phage display library technology which has underpinned this success. For example, we granted an exclusive license for an antibody phage display library to Agenus, an immunology company engaged in the discovery and development of novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases.